Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Chemical Works of Gedeon Richter's Intrinsic Value: Projected FCF or its related term are showing as below:
RGEDF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.71 Med: 1.1 Max: 1.37
Current: 0.93
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Chemical Works of Gedeon Richter was 1.37. The lowest was 0.71. And the median was 1.10.
RGEDF's Price-to-Projected-FCF is ranked better than 72.13% of 635
companies
in the Drug Manufacturers industry
Industry Median: 1.53
vs RGEDF: 0.93
Chemical Works of Gedeon Richter (OTCPK:RGEDF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Chemical Works of Gedeon Richter's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
40.9125
/
58.125429785197
=
0.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Intrinsic Value: Projected FCF Related Terms
Chemical Works of Gedeon Richter Intrinsic Value: Projected FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Intrinsic Value: Projected FCF Chart
RGEDF vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Price-to-Projected-FCF falls into.
Chemical Works of Gedeon Richter Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $43.79 mean?
Chemical Works of Gedeon Richter (RGEDF) has a Intrinsic Value: Projected FCF of $43.79 as of Sep. 22, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Chemical Works of Gedeon Richter and its competitors. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #177 out of 635 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Chemical Works of Gedeon Richter's Intrinsic Value: Projected FCF too high?
Chemical Works of Gedeon Richter's current Intrinsic Value: Projected FCF is $43.79. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.53. Chemical Works of Gedeon Richter's value of $43.79 is 2762.1% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #177 out of 635 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #177 out of 635 companies for Intrinsic Value: Projected FCF. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.53. Chemical Works of Gedeon Richter's value of $43.79 is 2762.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.53, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current Intrinsic Value: Projected FCF of $43.79 is 2762.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Intrinsic Value: Projected FCF is $43.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Fairly Valued. The stock's GF Value™ is $37.56, compared to a current price of $40.91 — trading 8.9% above its estimated fair value. The current Intrinsic Value: Projected FCF is $43.79 and 2762.1% above the Drug Manufacturers industry median of 1.53. Chemical Works of Gedeon Richter's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Intrinsic Value: Projected FCF is $43.79 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $40.91 is trading 8.9% above its estimated GF Value™ of $37.56.
GuruFocus considers Chemical Works of Gedeon Richter to be Fairly Valued.
Key valuation signals for RGEDF:
Intrinsic Value: Projected FCF: $43.79
GF Value™: $37.56 vs. price of $40.91 (8.9% above fair value)
Industry Position: 2762.1% above the Drug Manufacturers median (#177 of 635)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
91GF Score
Get the complete analysis for RGEDF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
